Companion Diagnostics Market to Enjoy 'Explosive Growth' to 2032| Biogenex Laboratories, Guardant Health, Abnova

DiMarket published a new research publication on "Companion Diagnostics Market" with 230+ pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Companion Diagnostics market was mainly driven by the increasing R&D spending across the world.

Some of the key players profiled in the study are: Myriad Genetics Inc, Biomerieux, Guardant Health Inc, Abnova Corporation, Almac Group, Thermo Fisher Scientific Inc, F Hoffmann-La Roche Ltd, Siemens Healthineers AG, Agilent Technologies Inc, Abbott, Qiagen NV, Sysmex Corporation, Illumina Inc, Biogenex Laboratories Inc , Danaher Corporation (Beckman Coulter Inc.

Get Free Exclusive PDF Sample Copy of This Research 👉 https://datainsightsmarket.com/report/companion-diagnostics-industry-7744/sample-report?utm_source=Lal_OpenPR&utm_id=Lal

Scope of the Report of Companion Diagnostics:
The size of the Companion Diagnostics Industry market was valued at USD 7.74 Million in 2023 and is projected to reach USD 17.70 Million by 2032, with an expected CAGR of 12.54% during the forecast period. The Companion Diagnostics Industry deals with the use of diagnostic tools that help in determining the right kind of treatment for a specific patient due to his/her genetic, molecular or biochemical makeup. These tests play an important role in management as they help in defining the patients who are likely to benefit from a particular drug or treatment in for example oncology. Some of them include the introduction and application of other high technological system like the next-generation sequencing (NGS) and the liquid biopsy techniques. It is, therefore, propelled by the need for the targeted therapies, and high incidence of cancer and expansion of targeted therapies. Pharmaceutical industry alliances with developers of diagnostics, and regulatory backing to companion diagnostics also add to the market's growth.

The titled segments and sub-section of the market are illuminated below: By Technology: Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing, Other Technologies, By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Other

Market Drivers:
Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option; Increasing Cases of Adverse Drug Reactions; Co-development of Drug and Diagnostic Technologies

Market Trends:
The Lung Cancer Segment is Expected to Witness Significant Growth Over the Forecast Period

Restrains:
High Cost of Drug Development and Associated Clinical Trials; Reimbursement Issues Among Many Countries

Have Any Questions Regarding Global Companion Diagnostics Market Report, Ask Our Experts 👉 https://datainsightsmarket.com/report/companion-diagnostics-industry-7744/enquiry-before-buy?utm_source=Lal_OpenPR&utm_id=Lal

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Significant developments in Companion Diagnostics Industry Sector:
1. April 2024: Roche received approval of the CE Mark for the VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression who can be given ENHERTU (trastuzumab deruxtecan) as a targeted treatment.

2. April 2024: Transcenta Holding Limited collaborated with Agilent Technologies to develop Claudin18.2 (CLDN18.2), a companion diagnostic, to support the TranStar301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.

3. February 2024: Roche signed an agreement with PathAI, a global company active in AI-powered technology for pathology. Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space.

Strategic Points Covered in Table of Content of Global Companion Diagnostics Market:
Chapter 1: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Companion Diagnostics
Chapter 2: Evaluating the leading manufacturers of the Companion Diagnostics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 3: Introduction, market driving force product Objective of Study and Research Scope the Companion Diagnostics market
Chapter 4: Exclusive Summary - the basic information of the Companion Diagnostics Market.
Chapter 5: Presenting the Companion Diagnostics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 6: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2024-2032)
Chapter 7: Displaying the by Type, End User and Region/Country 2019-2023
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

finally, Companion Diagnostics Market is a valuable source of guidance for individuals and companies.

Read Detailed Index of full Research Study at 👉 https://datainsightsmarket.com/reports/companion-diagnostics-industry-7744?utm_source=Lal_OpenPR&utm_id=Lal

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia.

Contact Us:
Craig Francis (PR & Marketing Manager)
DiMarket
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA - 08837
Phone: +1 2017933837, +44 20 7097 9277
sales@datainsightsmarket.com

About Author: DiMarket is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies' revenues.
Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

This release was published on openPR.